InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Announcements

Current share price for AGN : $0.130 0.01 (7.14%)+

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$17 Application for quotation of securities - AGN 5 Jun 2024 8:23AM $0.730 $0.130 fallen by 82.19%
$17 ARG-007 Reduces Effects of TBI in Preclinical Study 15 May 2024 8:25AM $0.650 $0.130 fallen by 80%
$17 DSMB Confirms Safety of First Patients Dosed 29 Apr 2024 9:02AM $0.565 $0.130 fallen by 76.99%
$17 Quarterly Activities/Appendix 4C Cash Flow Report 24 Apr 2024 8:47AM $0.545 $0.130 fallen by 76.15%
$17 Cleansing Notice 22 Apr 2024 9:18AM $0.570 $0.130 fallen by 77.19%
$17 Application for quotation of securities - AGN 22 Apr 2024 9:16AM $0.570 $0.130 fallen by 77.19%
$17 Proposed issue of securities - AGN 12 Apr 2024 9:14AM $0.635 $0.130 fallen by 79.53%
$17 Proposed issue of securities - AGN 12 Apr 2024 9:14AM $0.635 $0.130 fallen by 79.53%
$17 Argenica Successfully Completes $12.0m Placement 12 Apr 2024 9:14AM $0.635 $0.130 fallen by 79.53%
$17 Trading Halt 10 Apr 2024 9:12AM $0.635 $0.130 fallen by 79.53%
$17 Patient Dosing Milestone Achieved in Phase 2 Stroke Trial 10 Apr 2024 8:26AM $0.635 $0.130 fallen by 79.53%
$17 First Patient Dosed in Phase 2 Stroke Trial of ARG-007 28 Mar 2024 8:25AM $0.590 $0.130 fallen by 77.97%
$17 FDA Grants Rare Pediatric Disease Designation For HIE 25 Mar 2024 9:11AM $0.570 $0.130 fallen by 77.19%
$17 Application for quotation of securities - AGN 7 Mar 2024 4:44PM $0.600 $0.130 fallen by 78.33%
$17 Half Yearly Report and Accounts 28 Feb 2024 8:07AM $0.580 $0.130 fallen by 77.59%
$17 Application for quotation of securities - AGN 16 Feb 2024 4:47PM $0.540 $0.130 fallen by 75.93%
$17 Phase 2 Manufacturing Completed & Trial Update 12 Feb 2024 8:15AM $0.580 $0.130 fallen by 77.59%
$17 Cleansing Notice 2 Feb 2024 8:22AM $0.565 $0.130 fallen by 76.99%
$17 Application for quotation of securities - AGN 2 Feb 2024 8:22AM $0.565 $0.130 fallen by 76.99%
$17 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2024 8:23AM $0.565 $0.130 fallen by 76.99%
$17 Phase 2 Stroke Clinical Trial Update 14 Dec 2023 8:18AM $0.495 $0.130 fallen by 73.74%
$17 AGM Presentation 1 Dec 2023 8:17AM $0.430 $0.130 fallen by 69.77%
$17 Initial Director's Interest Notice 1 Dec 2023 8:16AM $0.430 $0.130 fallen by 69.77%
$17 Final Director's Interest Notice 1 Dec 2023 8:16AM $0.430 $0.130 fallen by 69.77%
$17 Amended Constitution 1 Dec 2023 8:16AM $0.430 $0.130 fallen by 69.77%

126 - 150 of 297 results

Page 6 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.